As the public health landscape surrounding COVID-19 continues to develop, Phase 4 studies play an essential role in understanding long-term vaccine performance. Evaluating how approved vaccines perform in real-world settings requires a strong operational foundation, especially when managing the nuances of interventional protocols.

Exceeding Expectations in COVID-19 Vaccine Research

Selected as a participating site network for a Phase 4 COVID-19 vaccine trial, DelRicht Research was entrusted with enrolling healthy adults aged 50-64. Our network was expected to enroll 433 participants across six sites. By study close, our teams collectively enrolled 713 qualified participants, reaching 164.5% of our expected enrollment goal while maintaining a 96.6% average retention rate. These achievements highlight the strength of DelRicht’s embedded research model and the collaboration between experienced investigators and dedicated site teams.

Leading enrollment volumes were Dr. Jonathan Jacobs (Overland Park, KS) and Dr. Matthew Mintz (Rockville, MD), whose sites ranked among the Top 10 highest enrollers studywide. They were joined by Dr. Patrick Dennis (New Orleans, LA), Dr. Sean Kerby (Gulfport, MS), Dr. Melita Tate (Tulsa, OK), and Dr. E. Marshall Newton (Charleston, SC), each contributing to a coordinated high-performing network that delivered consistent results and dependable data quality.

Overcoming Operational Challenges

Like many vaccine studies, this trial presented challenges that demanded both technical precision and patient support. Each participant required verified records of no prevalent high-risk conditions such as smoking, asthma, and common mood disorders. This recruitment step often introduces delays in screening and eligibility confirmation. Moreover, maintaining accurate daily eDiary entries from populations that may not be as familiar posed ongoing compliance challenges across study sites.

DelRicht addressed these hurdles through two key strategies:

1. Leveraging our existing referral network to identify qualifying vaccine patients with verified historical records to expedite eligibility confirmation and enrollment.

2. Utilizing proactive compliance monitoring through daily oversight. This process implemented real-time reminders and automated alerts, provided 24/7 support for troubleshooting technical issues, and assigned dedicated study coordinators for immediate follow-up if entries were missed. This patient-centered approach resulted in an ePRO compliance rate within 0.8% of the studywide average.

These solutions and efforts strengthened patient engagement and data integrity across all sites. Partner at DelRicht Research, Marshall Morris added:

“Complex vaccine protocols, like daily eDiaries and strict health histories, only succeed when participants feel fully supported. By pairing proactive, technical support with hands-on coordinator care, our teams kept participant engagement high throughout the study. That level of retention directly safeguards data integrity, ensuring sponsors get answers they can trust in rapid vaccine trial timelines.” – Marshall Morris, Partner at DelRicht Research

Partnering in Vaccine Research

At DelRicht Research, we go beyond enrollment, we build site-level strategies that drive efficiency, reduce variability, and deliver consistent results across even the most complex trials. The success of this vaccine trial reflects our continued commitment to offering research as a care option and partnering with sponsors and CROs who value speed, quality, and performance.

If you’re seeking a partner who can accelerate timelines and exceed expectations in vaccination trials, we’d love to connect. Learn more about our capabilities at www.DelRichtResearch.com or reach out to explore partnership opportunities.